Iovance Biotherapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 3.93, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Iovance Biotherapeutics Inc in Mar 31 2026 quarter, has decreased to 93 days, compared to 97 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 285 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1785, from overall ranking in the fourth quarter 2025 at 2372.

What is Receivable Turnover Ratio?
What is Iovance Biotherapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IOVA Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	15.25 %	18.9 %	19.71 %	89.65 %	30215.38 %
Y / Y Revenue Change	44.82 %	17.74 %	15.2 %	92.73 %	6798.46 %
Receivable Turnover Ratio (TTM)	3.93	3.76	3.75	3.77	3.74
IOVA's Total Ranking	# 1785	# 2372	# 2515	# 2413	# 2476
Accounts Receivable average collection period days	93	97	97	97	98
Seq. Receivable Change	-0.84 %	23.5 %	11.38 %	-15.51 %	2.3 %
Seq. Revenue Change	-17.68 %	28.64 %	12.52 %	21.55 %	-33.07 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 24
Healthcare Sector	# 286
Overall Market	# 1785

Receivable Turnover Ratio Statistics
High	Average	Low
0.31	0.18	0
(Mar 31 2026)		(Mar 31 2024)

IOVA Company Profile • Back to IOVA Efficiency Comparisons • Compare IOVA Receivables Turnover Ratio to its Competitors

Financial Statements
Iovance Biotherapeutics Inc 's Accounts Receivable	$ 82 Millions	Visit IOVA's Balance sheet
Iovance Biotherapeutics Inc 's Sales TTM	$ 286 Millions	Visit IOVA's Income Statement
Sources of IOVA's Revenues		Visit IOVA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IOVA's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IOVA's Growth Rates	IOVA's Roa	IOVA's Inventory Turnover Ratio	IOVA's Dividend Comparisons
IOVA's Profitability Ratios	IOVA's Roi	IOVA's Asset Turnover Ratio	IOVA's Dividend Growth
IOVA's Valuation Ratios	IOVA's Roe	IOVA's Financial Strength Ratios	IOVA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Biolife Solutions Inc	9.51	$ 99.673 Millions	$ 10.478 Millions
Biofrontera Inc	9.49	$ 42.983 Millions	$ 4.530 Millions
United Therapeutics Corporation	9.47	$ 3,169.800 Millions	$ 334.800 Millions
Tandem Diabetes Care Inc	9.34	$ 1,023.420 Millions	$ 109.550 Millions
Sunshine Biopharma Inc	9.33	$ 35.493 Millions	$ 3.804 Millions
The Oncology Institute Inc	9.30	$ 545.764 Millions	$ 58.671 Millions
The Pennant Group Inc	9.28	$ 1,023.227 Millions	$ 110.305 Millions
Enanta Pharmaceuticals Inc	9.26	$ 69.213 Millions	$ 7.477 Millions
Volitionrx Limited	9.23	$ 2.466 Millions	$ 0.267 Millions
Lucid Diagnostics Inc	9.11	$ 5.134 Millions	$ 0.564 Millions
Soleno Therapeutics Inc	9.09	$ 285.008 Millions	$ 31.369 Millions
Zomedica Corp	9.07	$ 34.660 Millions	$ 3.820 Millions
Dariohealth Corp	9.03	$ 20.983 Millions	$ 2.324 Millions
Harmony Biosciences Holdings inc	9.02	$ 899.247 Millions	$ 99.660 Millions
Tactile Systems Technology Inc	9.01	$ 343.414 Millions	$ 38.110 Millions
Ardent Health Inc	8.99	$ 6,428.975 Millions	$ 715.036 Millions
Sanuwave Health Inc	8.91	$ 44.328 Millions	$ 4.973 Millions
Biocryst Pharmaceuticals Inc	8.89	$ 885.716 Millions	$ 99.648 Millions
Madrigal Pharmaceuticals Inc	8.81	$ 1,132.490 Millions	$ 128.587 Millions
Inogen Inc	8.80	$ 351.497 Millions	$ 39.926 Millions
Grail Inc	8.77	$ 156.120 Millions	$ 17.809 Millions
Eyepoint Inc	8.76	$ 7.614 Millions	$ 0.869 Millions
Scientific Industries Inc	8.65	$ 6.588 Millions	$ 0.761 Millions
Sanara Medtech Inc	8.60	$ 106.873 Millions	$ 12.423 Millions
Protalix Biotherapeutics inc	8.57	$ 76.381 Millions	$ 8.912 Millions
Adapthealth Corp	8.55	$ 3,286.774 Millions	$ 384.194 Millions
Perrigo Company Plc	8.52	$ 4,177.500 Millions	$ 490.200 Millions
Alpha Teknova Inc	8.48	$ 43.582 Millions	$ 5.141 Millions
Ensign Group Inc	8.47	$ 5,273.996 Millions	$ 622.757 Millions
Axogen inc	8.41	$ 238.105 Millions	$ 28.322 Millions

Date modified: 2026-08-29T17:25:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.